No Data
No Data
No Data
No Data
No Data
Tengsheng Pharmaceutical-B (02137) granted a total of 5.752,500 share options and 821,500 restricted share units
Tengsheng Pharmaceutical-B (02137) issued an announcement. On March 28, 2024, the company purchased shares in accordance with 2023...
Zhitong FinanceMar 28 13:18 ET
Tengsheng Pharmaceutical-B (02137.HK) will actively seek external cooperation with R&D expenditure of 403 million yuan in 2023
Gelonghui, March 22 | Tengsheng Pharmaceutical-B (02137.HK) announced that for the year ended December 31, 2023, other revenue was RMB 163.7 million, an increase of RMB 55.8 million or 51.7% compared with RMB 107.9 million for the year ended December 31, 2022. This was mainly due to an increase in interest income of RMB 70.8 million due to rising interest rates on US dollar and Hong Kong dollar time deposits. This increase was partially offset by a reduction in revenue recognized by the Chinese government subsidy. For the year ended December 31, 2023, R&D expenditure was for the people
Gelonghui FinanceMar 22 07:07 ET
BRII-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Futu NewsMar 22 07:00 ET · Announcements
Tengsheng Pharmaceutical-B (02137.HK) will hold a board meeting on March 22 to approve the annual results
Gelonghui March 11 | Tengsheng Pharmaceutical-B (02137.HK) issued an announcement. The company will hold a board meeting on March 22, 2024 to review and approve the company's annual results and announcements for the year ended December 31, 2023.
Gelonghui FinanceMar 11 04:42 ET
BRII-B: DATE OF BOARD MEETING
Futu NewsMar 11 04:39 ET · Announcements
After falling nearly 45% in two days and excluding Hong Kong Stock Connect, Tengsheng Pharmaceutical-B (02137) was seriously injured?
As the stock with the worst decline on the list, the reason behind the successive sharp declines of Tengsheng Pharmaceutical-B is not just an appearance on paper.
Zhitong FinanceMar 5 07:46 ET
No Data
No Data